Peak Design's new portable pro tripods can support up to 40 pounds of camera gear
Peak Design has announced three new tripods with features and functionality that cater to professional photographers and videographers. The company's first tripod was a travel model that folded to be as slim as a soda can to prioritize portability. Its new pro tripods, available in three versions, are slightly thicker when collapsed, but they can also support twice as much weight and stand a bit taller.
The company is once again launching the new tripods through a Kickstarter crowdfunding campaign today. The new pro versions range in price from $799.95 to $999.95 — a big jump from the starting price of its original Travel Tripod at $349.95. However, the earliest backers can preorder them with discounts up to 27 percent off.
The three new models include the standard Pro Tripod and two variants. The Pro Lite Tripod is lighter and packs down smaller, thanks to its legs and center column being scaled down. The Pro Tall Tripod features elongated legs so it stands taller, but it also maximizes stability since the center column may not need to be extended as high.
Ranging in weight from 3.7 to 4.5 pounds, the new pro models are only slightly heavier than Peak Design's aluminum Travel Tripod, which weighs 3.44 pounds. But they all stand much taller, up to 77.7 inches for the Pro Tall Tripod, and can support up to 40 pounds of camera equipment, although the smaller Pro Lite Tripod maxes out at 35 pounds.
Despite their thicker and sturdier legs made of carbon fiber, you can still squeeze the new pro tripods into a backpack's side pocket because the largest model measures just 3.66 inches in diameter when folded down. (Peak Design's Travel Tripod was 3.25 inches, for comparison.) But they may stick out a bit more since they're 4 to 7 inches taller.
Peak Design is carrying forward some of the more unique features of its Travel Tripod, including a smartphone mount and a hex multitool that both fold down so they can be stowed inside the tripod's center column. They'll also have better Arca-compatible quick-lock grips that hold a camera more securely while making it easier to attach and remove. And you can get an optional $149.95 Tilt Mod accessory that converts the pro tripods' easily adjustable ball head into a fluid pan and tilt head for smoother camera movements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Forbes
25 minutes ago
- Forbes
Google's Quiet Confirmation Of The Pixel 10
Google's "Talking Phones Podcast" title card Google is having a little bit of fun in its latest iPhone vs Pixel video. While the Pixel 9 Pro takes pride of place, there's also a surprising cameo for what comes next… the Pixel 10. The Pixel 10 Easter Egg The details come at the end of Google's latest promotional video posted on its Made By Google YouTube channel. In it, an iPhone and a Pixel talk about the recent advances made by Apple's smartphone, with a not at all surprised Pixel noting when that feature arrived on Pixel and Android. These include live translation, hold assistance and call screening arriving four, five and seven years ago respectively., Of course, the capabilities of all these features have improved significantly over the last few years, so there are shades of Oranges to (ahem) Apples here, but it makes Google's point effectively. The story of Android being ahead of iOS is here for all to hear. The little easter egg at the end is part of another story, leading into the next Pixel release. The iPhone quietly asks the Pixel 9 Pro, 'so, what are you working on for Pixel 10… just out of curiosity?' Naming The Pixel 10 It's no secret that Google is working on the next family of Pixel smartphones. Neither is it a secret that we're expecting an entry-level Pixel 10, a premium Pixel 10 Pro, a larger Pixel 10 Pro XL and an innovative Pixel 10 Pro Fold. Yet this is the first time Google has publicly acknowledged that the new handsets will carry the Pixel 10 branding. Although the sharp-eared watchers will note that it was the iPhone confirming the new Pixel 10, not the Pixel 9 Pro. So, did Apple confirm the new name, rather than Google? Google is expected to announce the Pixel 10 family at an upcoming Made By Google event. While dates have not been confirmed, talk within the community picks out Wednesday, Aug. 20 for the launch, and Thursday, Aug 28. for the first handsets to go on sale to the public. Now read how the Pixel 10 will impact every Android smartphone in 2025 and beyond…
